Cochrane Multiple Sclerosis and Rare Diseases of the CNS review group is excited to share the publication of its 2024-2025 Annual Report, which highlights our activities, achievements, and collaborations over the past year.

This year, we continued our mission to produce high-quality systematic reviews on priority questions in multiple sclerosis and rare neurological diseases. Beyond producing reviews, we placed a strong emphasis on knowledge translation. These initiatives helped to make evidence more accessible and understandable, ensuring that it can be effectively applied in practice.

The 2024-2025 Report is more than a record of what we achieved. It is also a roadmap for future priorities, from advancing evidence synthesis in under-researched areas to broadening our global collaborations. Our work will continue to focus on ensuring that evidence is not only produced but also disseminated and implemented in ways that directly benefit the MS community.

We would like to express our gratitude to our collaborators and volunteers whose contributions and commitment made this year’s achievements possible. We are also grateful for the support of CET at Cochrane, which plays a key role in helping us deliver timely and trusted evidence worldwide.

The full report is now available, and we encourage our community to read it, share it, and engage with us on how we can continue to strengthen the impact of evidence in multiple sclerosis and rare diseases of the CNS.

Dowload it here: Report 2024-2025